Orient Pharma Co (ROCO:4166) Debt-to-Equity : 0.31 (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Orient Pharma Co Debt-to-Equity?

Orient Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$309 Mil. Orient Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$238 Mil. Orient Pharma Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was NT$1,788 Mil. Orient Pharma Co's debt to equity for the quarter that ended in Dec. 2024 was 0.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Orient Pharma Co's Debt-to-Equity or its related term are showing as below:

ROCO:4166' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.33 Max: 0.47
Current: 0.31

During the past 13 years, the highest Debt-to-Equity Ratio of Orient Pharma Co was 0.47. The lowest was 0.12. And the median was 0.33.

ROCO:4166's Debt-to-Equity is ranked worse than
54.03% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs ROCO:4166: 0.31

Orient Pharma Co Debt-to-Equity Historical Data

The historical data trend for Orient Pharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orient Pharma Co Debt-to-Equity Chart

Orient Pharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.27

0.37

0.47

0.43

0.31

Orient Pharma Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.47	0.44	0.43	0.37	0.31

Competitive Comparison of Orient Pharma Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orient Pharma Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Orient Pharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Orient Pharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(308.733	+	238.051)	/	1787.584
	=	0.31

Orient Pharma Co's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(308.733	+	238.051)	/	1787.584
	=	0.31

Orient Pharma Co (ROCO:4166) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Orient Pharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Orient Pharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Orient Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orient Pharma Co Ltd (ROCO:4166) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106

Website

http://www.oppharma.com

Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The company uses its platform technologies for the development of specialty pharmaceutical products and is capable of manufacturing products under cGMP. It provides drugs for treating Alzheimer's disease, psychostimulants, and treating Parkinson's disease.

Orient Pharma Co Headlines

No Headlines